Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
Reviva Pharmaceuticals (NASDAQ: RVPH) has announced it will present topline data from the long-term open label extension portion of its Phase 3 RECOVER study for brilaroxazine in schizophrenia treatment at the 2025 SIRS Congress in Chicago.
The presentation, titled 'Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants,' will be delivered by Dr. Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals, on Sunday, March 30th from 10:30 AM to 12:00 PM CST.
The company, which focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, will showcase these results at the Schizophrenia International Research Society (SIRS) Congress, taking place March 29 to April 2, 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha annunciato che presenterà i dati preliminari della parte di estensione a lungo termine in aperto del suo studio di Fase 3 RECOVER per brilaroxazina nel trattamento della schizofrenia al 2025 SIRS Congress di Chicago.
La presentazione, intitolata 'Valutazione in Aperto della Efficacia e Sicurezza di Brilaroxazina in Fase 3 per 52 Settimane in Partecipanti Stabili con Schizofrenia,' sarà tenuta dal Dr. Laxminarayan Bhat, Fondatore e CEO di Reviva Pharmaceuticals, domenica 30 marzo dalle 10:30 alle 12:00 CST.
L'azienda, che si concentra sullo sviluppo di terapie per il sistema nervoso centrale (CNS), malattie infiammatorie e cardiometaboliche, presenterà questi risultati al Congresso della Schizophrenia International Research Society (SIRS), che si svolgerà dal 29 marzo al 2 aprile 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha anunciado que presentará los datos preliminares de la parte de extensión a largo plazo del estudio de Fase 3 RECOVER para brilaroxazina en el tratamiento de la esquizofrenia en el 2025 SIRS Congress en Chicago.
La presentación, titulada 'Evaluación Abierta de 52 Semanas de Eficacia y Seguridad de Brilaroxazina en Fase 3 en Participantes Estables con Esquizofrenia,' será realizada por el Dr. Laxminarayan Bhat, Fundador y CEO de Reviva Pharmaceuticals, el domingo 30 de marzo de 10:30 AM a 12:00 PM CST.
La empresa, que se centra en desarrollar terapias para el sistema nervioso central (CNS), enfermedades inflamatorias y cardiometabólicas, mostrará estos resultados en el Congreso de la Sociedad Internacional de Investigación en Esquizofrenia (SIRS), que se llevará a cabo del 29 de marzo al 2 de abril de 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 브릴라록사진의 정신분열증 치료를 위한 3상 RECOVER 연구의 장기 개방형 확장 부분에서의 주요 데이터를 2025 SIRS Congress에서 시카고에서 발표할 것이라고 발표했습니다.
‘브릴라록사진 3상 RECOVER 52주 개방형 평가의 효과 및 안전성에 대한 연구’라는 제목의 발표는 Reviva Pharmaceuticals의 창립자이자 CEO인 Dr. Laxminarayan Bhat가 3월 30일 일요일 오전 10시 30분부터 오후 12시까지 CST에 진행할 예정입니다.
중추신경계(CNS), 염증 및 심혈관 대사 질환을 위한 치료제를 개발하는 데 중점을 둔 이 회사는 2025년 3월 29일부터 4월 2일까지 열리는 정신분열증 국제 연구 학회(SIRS)에서 이러한 결과를 발표할 것입니다.
Reviva Pharmaceuticals (NASDAQ: RVPH) a annoncé qu'il présentera les données préliminaires de la partie d'extension à long terme de son étude de Phase 3 RECOVER pour brilaroxazine dans le traitement de la schizophrénie lors du 2025 SIRS Congress à Chicago.
La présentation, intitulée 'Évaluation Ouverte de 52 Semaines de l'Efficacité et de la Sécurité de Brilaroxazine en Phase 3 chez des Participants Stables atteints de Schizophrénie,' sera faite par le Dr. Laxminarayan Bhat, Fondateur et PDG de Reviva Pharmaceuticals, le dimanche 30 mars de 10h30 à 12h00 CST.
L'entreprise, qui se concentre sur le développement de thérapies pour le système nerveux central (SNC), les maladies inflammatoires et cardiométaboliques, présentera ces résultats au Congrès de la Société Internationale de Recherche sur la Schizophrénie (SIRS), qui se tiendra du 29 mars au 2 avril 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) hat angekündigt, dass es die vorläufigen Daten aus dem langfristigen offenen Erweiterungsteil seiner Phase-3-Studie RECOVER für Brilaroxazin zur Behandlung von Schizophrenie auf dem 2025 SIRS Congress in Chicago präsentieren wird.
Die Präsentation mit dem Titel 'Brilaroxazin Phase 3 Recover 52-Wochen Offene Bewertung der Wirksamkeit und Sicherheit über 12 Monate bei stabilen Schizophrenie-Teilnehmern' wird am Sonntag, den 30. März, von 10:30 bis 12:00 Uhr CST von Dr. Laxminarayan Bhat, Gründer und CEO von Reviva Pharmaceuticals, gehalten.
Das Unternehmen, das sich auf die Entwicklung von Therapien für das zentrale Nervensystem (ZNS), entzündliche und kardiometabolische Erkrankungen konzentriert, wird diese Ergebnisse auf dem Kongress der Schizophrenia International Research Society (SIRS) präsentieren, der vom 29. März bis 2. April 2025 stattfindet.
- None.
- None.
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S.
Details for the oral presentation can be found below:
Title: Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants
Session: Pharmaceutical Pipeline
Date and Time: Sunday, March 30th from 10:30 AM – 12:00 PM ET CST
Presenter: Dr. Laxminarayan Bhat, Founder & CEO, Reviva Pharmaceuticals
Abstracts and additional details can be found at the SIRS 2025 website.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
What are the key findings from RVPH's Phase 3 RECOVER study for brilaroxazine?
When and where will Reviva Pharmaceuticals (RVPH) present its brilaroxazine study results?
What is the duration of the RVPH RECOVER study for brilaroxazine in schizophrenia?
Which therapeutic areas does RVPH focus on with brilaroxazine development?
